Dabrafenib (Tafinlar)
Targeted Therapy · Approved since 2013
Description
Dabrafenib is a selective BRAF kinase inhibitor used in the treatment of metastatic colorectal cancer harboring BRAF V600E mutations. This targeted therapy is employed in combination regimens with other agents such as anti-EGFR antibodies (cetuximab or panitumumab) and chemotherapy backbones like FOLFOX for patients with advanced disease. Dabrafenib specifically addresses the therapeutic challenge posed by BRAF-mutated colorectal cancers, which represent approximately 8-15% of metastatic cases and historically demonstrate poor response to standard treatments.
Mechanism of Action
Dabrafenib selectively inhibits mutant BRAF V600E kinase, blocking aberrant MAPK pathway signaling that drives tumor cell proliferation and survival. By targeting this specific oncogenic mutation, the drug disrupts the downstream cascade of cellular signals that promote cancer growth and metastasis.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Tafinlar |
| Category | Targeted Therapy |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | Oral |
| Year Approved | 2013 |
| Clinical Trials | 9 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.